Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Acasti Pharma Inc ACST

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.


NDAQ:ACST - Post by User

Comment by Francine01on Aug 31, 2020 10:15am
243 Views
Post# 31478880

RE:RE:Francine

RE:RE:Francine Indeed sad morning.

I still do believe that Capre works because 38.4% HTG after 26 weeks, is not the act god. 

The only information that we have is primary end point 12 weeks. 

This morning, we have 0 information, the placebo 17,9% reduction. Is it the average of weeks -2, -1 and 0 or at week 0 ? 

They didn't not control the enrolment background and patients were not stabilized before randomzation.

This is a story of trial incorrectly managed by Acasti management and CRO.

Board should seek for a financial advisor to review all stategic options. Since I am based in Montreal, I could coordinate on behalf of shareholders. I will talk to other shareholders in the followind days. 

I don't see Jan be part of any plan. Shareholders meeting is end of September, Jan should resign to avoid the disgrace of beeing kick out. 

The company is bassicaly trading for cash in bank account. There is no point for shareholders to sold shares. 

PS. boozer. I didn't sold any share. 



<< Previous
Bullboard Posts
Next >>